TECH logo

BIO-TECHNE CORP

TECHNASDAQ
πŸ† #647 by market capEarnings Aug 12US Equity
$72.15β–² $0.03 (+0.04%)
Live
1hβ€”
24hβ–² 0.0%
7dβ€”
14dβ€”
30dβ€”
1yβ€”
🏦Market Cap
$11.24B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+0.2%
Slowing
πŸ“ŠGross Margin
66.4%
High
πŸ’΅FCF Margin
22.3%
Strong
βš–οΈP/S Ratio
9.3x
Elevated
Otter Score
47
Weak
No chart data available for TECH.

Trading Snapshot

Day Range
$71.65 – $72.73
52-Week Range
$43.20 – $72.39
Volume
$3.78B
Avg Volume
$4.81B
Shares Outstanding
155.8M
Next Earnings
Sep 30, 2026

Fundamentals Snapshot

Annual Revenue
$1.22B
Last Q Revenue
$311M
P/E Ratio
104.3
P/S Ratio
9.3x
EPS (TTM)
$0.69
Dividend Yield
0.44%

Why Investors Own TECH

  • βœ“High-growth profile β€” revenue up -3.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 60% gross margin and 12% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$1.22Bβ–² +0.2% YoY
Gross Margin (TTM)
60.1%β–Ό βˆ’0.5% YoY
Operating Income (TTM)
$341Mβ–² +0.2% YoY
Free Cash Flow (TTM)
$145Mβ–² +0.2% YoY

About BIO-TECHNE CORP

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
47/100

Analyst Ratings

β“˜
Consensus
Buy
22 analysts
Strong Buy3
Buy6
Hold13
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

YahooΒ·4d ago

Is Bio-Techne (TECH) Above Fair Value After A 44% Return?

Bio-Techne stock has delivered a strong 44.2% return over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a premium rather than as an obvious bargain. Over the last 12 months, Bio-Techne has returned 44.2%, which puts a clear spotlight on whether recent gains already reflect much of the good news in the price. Expectations around Bio-Techne's ability to grow revenue and sustain healthy cash flows...

YahooΒ·5d ago

JAZZ vs. TECH: Which Stock Is the Better Value Option?

JAZZ vs. TECH: Which Stock Is the Better Value Option?

YahooΒ·5d ago

Investors’ Confidence in Bio-Techne Corp. (TECH) Strengthens as Headwind Eases

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]

YahooΒ·7d ago

2 S&P 500 Stocks to Keep an Eye On and 1 We Turn Down

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

YahooΒ·7d ago

1 Healthcare Stock Worth Your Attention and 2 We Question

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 16.6% over the past six months while the S&P 500 was up 7.1%.

SeekingAlphaΒ·11d ago

Madison Mid Cap Fund Q2 2026 Portfolio Activity

The top five contributors for the quarter were MKS, Amphenol, Arista Networks, Bio-Techne, and Waters.